Hainan Huluwa Pharmaceutical Group Co Ltd (SHG:605199) — Market Cap & Net Worth
Market Cap & Net Worth: Hainan Huluwa Pharmaceutical Group Co Ltd (605199)
Hainan Huluwa Pharmaceutical Group Co Ltd (SHG:605199) has a market capitalization of $397.54 Million (CN¥2.72 Billion) as of May 5, 2026. Listed on the SHG stock exchange, this China-based company holds position #13716 globally and #4323 in its home market, demonstrating a 1.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hainan Huluwa Pharmaceutical Group Co Ltd's stock price CN¥6.79 by its total outstanding shares 400108752 (400.11 Million). Analyse cash efficiency ratio of Hainan Huluwa Pharmaceutical Group Co Lt to see how efficiently the company converts income to cash.
Hainan Huluwa Pharmaceutical Group Co Ltd Market Cap History: 2020 to 2026
Hainan Huluwa Pharmaceutical Group Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $1.40 Billion to $397.54 Million (-1.54% CAGR).
Hainan Huluwa Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hainan Huluwa Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.66x
Hainan Huluwa Pharmaceutical Group Co Ltd's market cap is 0.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.40 Billion | $1.16 Billion | $121.50 Million | 1.21x | 11.56x |
| 2021 | $1.46 Billion | $1.35 Billion | $72.14 Million | 1.08x | 20.23x |
| 2022 | $937.95 Million | $1.52 Billion | $85.68 Million | 0.62x | 10.95x |
| 2023 | $887.60 Million | $1.80 Billion | $106.50 Million | 0.49x | 8.33x |
| 2024 | $932.68 Million | $1.41 Billion | -$274.46 Million | 0.66x | N/A |
Competitor Companies of 605199 by Market Capitalization
Companies near Hainan Huluwa Pharmaceutical Group Co Ltd in the global market cap rankings as of May 5, 2026.
Key companies related to Hainan Huluwa Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #497 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #524 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #531 globally with a market cap of $49.66 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #571 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #497 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #524 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #531 | Zoetis Inc | NYSE:ZTS | $49.66 Billion | $112.68 |
| #571 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $41.87 |
Hainan Huluwa Pharmaceutical Group Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Hainan Huluwa Pharmaceutical Group Co Ltd's market cap moved from $1.40 Billion to $ 397.54 Million, with a yearly change of -1.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥397.54 Million | -10.89% |
| 2025 | CN¥446.14 Million | -52.17% |
| 2024 | CN¥932.68 Million | +5.08% |
| 2023 | CN¥887.60 Million | -5.37% |
| 2022 | CN¥937.95 Million | -35.71% |
| 2021 | CN¥1.46 Billion | +3.87% |
| 2020 | CN¥1.40 Billion | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Hainan Huluwa Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $397.54 Million USD |
| MoneyControl | $397.54 Million USD |
| MarketWatch | $397.54 Million USD |
| marketcap.company | $397.54 Million USD |
| Reuters | $397.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more